Characteristic | No. (%) of patients* | p value† | |
---|---|---|---|
Control group n = 58 | Tranexamic acid group n = 58 | ||
Demographic | |||
Age, mean ± SD; yr | 75.12 ± 6.20 | 75.57 ± 6.35 | 0.08 |
Sex | 0.5 | ||
Female | 42 (72) | 42 (72) | |
Male | 16 (28) | 16 (28) | |
Body mass index, mean ± SD | 28.3 ± 4.52 | 27.8 ± 4.73 | 0.2 |
ASA classification | 0.5 | ||
II | 11 (19) | 11 (19) | |
III | 47 (81) | 47 (81) | |
Preoperative laboratory values, mean ± SD | |||
Hemoglobin level, g/L | 131.07 ± 11.58 | 132.67 ± 11.31 | 0.4 |
Platelet count, × 109/L | 245 ± 63 | 250 ± 82 | 0.5 |
International normalized ratio | 1.02 ± 0.05 | 0.98 ± 0.06 | 0.7 |
Surgery | |||
Surgical site | 0.5 | ||
Right | 31 (53) | 30 (52) | |
Left | 27 (47) | 28 (48) | |
Surgical duration, mean ± SD; min | 84.12 ± 23.61 | 76.60 ± 17.67 | 0.08 |
Prosthesis | 0.5 | ||
DePuy Synthes, Johnson & Johnson | 50 (86) | 40 (69) | |
Zimmer Biomet | 8 (14) | 18 (31) | |
Anesthesia | 0.5 | ||
General | 19 (33) | 14 (24) | |
Spinal | 39 (67) | 44 (76) | |
Patients per surgeon | |||
Surgeon 1 | 0 (0) | 38 (66) | |
Surgeon 2 | 5 (9) | 20 (34) | |
Surgeon 3 | 27 (47) | 0 (0) | |
Surgeon 4 | 17 (29) | 0 (0) | |
Surgeon 5 | 9 (16) | 0 (0) | |
Tranexamic acid dosage, mean ± SD; mg/kg | — | 18.07 ± 3.59 |